Healthcare Review: Neuralstem, Addus Homecare, Keryx Biopharmaceuticals, Immunomedics, SIGA Technologies Print E-mail
By Staff and Wire Reports   
Tuesday, 16 July 2013 13:40
Stocks declined on the back of lackluster earnings results as investors looked ahead to Federal Reserve Chairman Ben Bernanke's congressional testimony on Wednesday. Through Monday, the S&P 500 had gained for eight-straight sessions, the longest win streak since January. And the Russell 2000 index of small-capitalization stocks had closed at seven-straight record highs, the longest stretch since October 1997. And the technology-friendly Nasdaq 100 rose for 14-straight sessions, the most since May 1990.

Neuralstem, Inc. (NYSEMKT:CUR) shares declined 9.60% to $1.60 in the morning hour. The company on June 10 reported that Eva Feldman , MD, PhD, will address the Canadian Neurological Sciences Federation Annual Congress, in Montreal , Canada , on Thursday, June 13 th at 8:30 a.m. ET as a grand plenary speaker (http://congress.cnsfederation.org/). Dr. Feldman will present final data from Neuralstem's Phase I trial testing NSI-566 spinal cord-derived neural stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease).

Addus Homecare Corporation (NASDAQ:ADUS) stock dropped 12.97% to $20.07. ADUS;s stock was downgraded by stock analysts at Robert W. Baird to a “neutral” rating in a report issued on July 16. Separately, Zacks cut shares of ADUS from an outperform rating to a neutral rating in a research report sent to investors on July 5. The firm currently has $21.50 price target on the stock.

Keryx Biopharmaceuticals (NASDAQ:KERX) shares gained 7.82% to $9.02. J.P. Morgan analyst Cory Kasimov initiated coverage on Keryx Biopharmaceuticals on June 19 with a rating of Overweight and a price target of $13.

Additionally, the company on June 3 announced the presentation of updated efficacy and safety data from the Phase 3 long-term clinical trial of Zerenex (ferric citrate), the Company's ferric iron-based phosphate binder drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with end-stage renal disease (ESRD) on dialysis.

Immunomedics, Inc. (NASDAQ:IMMU) shares jumped 6.06% to $6.65. The company on July 16 reported the issuance of U.S. Patent 8,486,395 with expiration on August 2, 2024. The new patent covers additional claims for the patent family, "Anti-CD19 Antibodies." The allowed claims protect our new, proprietary humanized hA19 antibody and cover its use for the treatment of B-cell lymphoma, chronic lymphocytic leukemia or acute lymphocytic leukemia.

SIGA Technologies, Inc. (NASDAQ:SIGA) stock gained 6.46% to $3.46. The company, on July 16, announced it has passed another significant commercial milestone with the third delivery of its proprietary smallpox antiviral drug, Arestvyr™, to the United States Government's Strategic National Stockpile (SNS). With a cumulative delivery of approximately 590,000 courses of Arestvyr to the SNS over the past five months, SIGA has met a key requirement of its contract with the Government's Biomedical Advanced Research and Development Authority (BARDA) and has qualified for a payment of approximately $79 million for the courses delivered to date.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter